Updates on Cell Therapy Symposium

The symposium will feature a keynote address from Dr. Carl June, Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine from University of Pennsylvania, setting the stage for an engaging event. Attendees can look forward to insightful presentations and discussions led by top scientists specializing in immunology, translational research, and innovative cell therapies. The symposium aims to foster collaboration and showcase the latest advancements in cell therapy, providing a valuable platform for exploring novel strategies in cancer treatment and improving patient outcomes.

1. Identify appropriate patient populations for current and investigational cell therapies.
2. Incorporate emerging biomarker and immune-monitoring strategies into practice.
3. Evaluate the risk-benefit profile of novel therapies based on up-to-date clinical trial data.
4. Create multidisciplinary care models that support cell therapy integration.

Advanced registration is encouraged.  Registration will close on January 23, 2026.

Registration is free for the Updates on Cell Therapy Symposium taking place on January 30, 2026.  

The Symposium will be held at MD Anderson Center, Main Building Floor 11, Hickey Auditorium, Room R11.1400, 1515 Holcombe Blvd. Houston, TX 77030, Houston, TX 77030, from 8 a.m. – 5 p.m. Registration is limited to 225 in-person attendees.

REGISTRATION CATEGORIES

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The University of Texas MD Anderson Cancer Center designates this live activity will award 7.75 Nursing Contact Hour(s).

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.